Pacira Q1 revenue beats estimates, co raises 2026 outlook

Pacira Biosciences

30/04/2026 21:19

Overview

U.S. pain therapy maker's Q1 revenue up 5%, beating analyst expectations

Adjusted EPS for Q1 beat consensus; adjusted net income and EBITDA missed estimates

Company repurchased 2.2 mln shares for $50 mln in Q1

Outlook

Pacira reiterates 2026 total revenue guidance of $745 mln to $770 mln

Company expects 2026 EXPAREL net product sales of $600 mln to $620 mln

Pacira anticipates key clinical trial readouts for ZILRETTA and PCRX-201 later in 2026

Result Drivers

EXAREL VOLUME GROWTH - Co said EXPAREL sales rose on 7% volume growth, though offset by vial mix shifts, discounting from new GPO partnership, and returns tied to winter storm

PORTFOLIO EXPANSION - Co attributed revenue growth to increased sales across EXPAREL, ZILRETTA, and iovera°, supported by expanding market access and adoption

REAL-WORLD EVIDENCE - Co highlighted real-world studies showing EXPAREL use linked to lower healthcare costs and reduced opioid use in orthopedic procedures

Company press release: ID:nGNX30VMZb

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$177 mln
$173.33 mln (6 Analysts)
Q1 Adjusted EPS
Beat
$0.60
$0.56 (7 Analysts)
Q1 Adjusted Net Income
Miss
$24.50 mln
$24.76 mln (5 Analysts)
Q1 Net Income
$2.90 mln
Q1 Adjusted EBITDA
Miss
$40.20 mln
$40.75 mln (4 Analysts)
Q1 Cash & Investments
$202.20 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Pacira Biosciences Inc is $27.00, about 7.4% above its April 29 closing price of $25.14

The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 8 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)